Tagged with Eye

Poland Stefan Jaworski-Martycz, country manager Poland and CEE Cluster Lead of Théa, a leading French ophthalmology company, discusses the intricacies of the Polish ophthalmology environment and the key steps for the Polish government to better value eyecare innovation. Additionally, he highlights the key growth drivers for the affiliate and the close…

Canada Mark Smithyes, president of Labtician Théa, highlights the company’s ambition to become the leader and preferred partner to optometrists and ophthalmologists in Canada by launching products from Laboratoires Théa’s innovative portfolio and building on Labtician Ophthalmics’ excellent reputation. Mark, what were the decisive pinpoints behind the joint venture between Labtician…

India Nikhil Masurkar, executive director of Entod Pharmaceuticals, talks about the company’s ambition to invest in stem cell research and become market leaders in the field of ophthalmology in ten years’ time by adding more cost-effective and highly effective dosage forms to their strong product portfolio. Can you briefly introduce your…

Brazil Luciano Marques, president of Alcon Brazil, provides insights into recent investments and innovative initiatives aimed at strengthening Alcon’s relationships with its partners and customers in Brazil, and also documents the heightening of the affiliate’s market access and medical affairs capacities and explains how these aspects have contributed to drive the…

Tunisia Mohamed Khalil Tamim, Alcon’s head of regulatory affairs Africa manages the regulatory affairs of 47 countries in Alcon’s African cluster. He explains the necessity of creating and harmonizing medical device-specific regulatory frameworks in Africa for the benefit of patients, and documents Alcon’s strategy to navigate a price-sensitive market despite its…

India Sanjay Bhutani, managing director of Bausch & Lomb India and SAARC operations, gives his insights into the thriving visual care industry which has allowed the company to launch 31 intraocular lenses (IOLs) in the last three years and the Good and Services Tax (GST) which presents somewhat of a barrier…

Austria Günther Aschenbrenner, managing director of Théa Austria, a specialist French ophthalmology company, discusses the development of the company’s Austrian office since 2011 and how a strong portfolio acquired by Théa from Alcon has assisted them in growing rapidly. Furthermore, he provides an insight into the importance of long-term strategic thinking,…

Pharma In an exclusive interview at the eyeforpharma Barcelona Summit 2016, Janssen EMEA’s Jane Griffiths speaks out about patient-centricity, sustainability and the dawning of a new world of healthcare. What’s been keeping you most busy in recent months? We have, for the third consecutive year, topped IDEA Pharma’s Productive Innovation Index (PII), which…

Pharma The pharmaceutical industry needs to work harder to demonstrate the value that it delivers to society and to the greater economy by advancing public health outcomes, delegates at the 14th annual eyeforpharma conference in Barcelona have been told. Addressing over a thousand industry stakeholders at Barcelona’s Centre Convencions Internacional, senior…

Pharma In part II of an exclusive interview at the eyeforpharma Barcelona Summit 2016, IMS Health’s Chief Digital Officer Richie Etwaru lifts the lid on the concept of Orchestrated Customer Engagement (OCE) and explains how it can demonstrably advance the ideals of patient centrality, inter-stakeholder trust and industry-wide operability. You have been pioneering…

Pharma Yann Quentric has assumed new responsibilities as president of Iris Pharma; leading the first CRO to specialize exclusively in ophthalmology. From the company’s humble beginnings in southern France to its current international reach, Mr. Quentric shares his vision on the next chapter for the company. Can you start by introducing Iris Pharma…

Pharma Théa’s Jean-Frederic Chibret reveals how as a company focused purely on ophthalmology, they have the expertise to focus on niche areas that big pharma companies neglect; how they are the third largest pharma ophthalmic company in Europe, and the only pan-European ophthalmic company to have its headquarters on the continent, and…